Literature DB >> 7902899

Respiratory syncytial virus or influenza?

D M Fleming1, K W Cross.   

Abstract

We compared data from clinical surveillance of acute respiratory infections in elderly people reported by a network of sentinel general practitioners, virus isolate data for respiratory syncytial virus (RSV) and influenza A and B viruses, and registered deaths, during the past four winters. Cases of acute respiratory disease (ARD) and deaths (3-week moving averages) showed strong similarity in timing. Periods of high incidence of ARD and numbers of deaths were followed within 2-3 weeks by reports of high numbers of RSV or influenza virus isolates. The epidemic period in December, 1989, was followed by high numbers of both virus isolates, but in all other epidemic periods one virus predominated. The lethality of epidemics due to RSV or influenza A or B varied both within and between years. These analyses suggest that RSV is as important as influenza viruses in causing morbidity and excess deaths among elderly people. RSV was prevalent at the end of each of the past four years in the UK; its importance as a cause of excess deaths would therefore be concealed in any analysis based on several years' experience. By contrast, the inconsistency of epidemics due to influenza viruses makes excess deaths due to these viruses easily recognisable. Integrated clinical and viriological surveillance is essential if epidemics due to RSV, influenza virus, or any other virus are to be correctly interpreted.

Entities:  

Mesh:

Year:  1993        PMID: 7902899     DOI: 10.1016/s0140-6736(05)80082-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  57 in total

1.  The duration and magnitude of influenza epidemics: a study of surveillance data from sentinel general practices in England, Wales and the Netherlands.

Authors:  D M Fleming; M Zambon; A I Bartelds; J C de Jong
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

2.  Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: results of a multivariate time-series analysis.

Authors:  R E G Upshur; R Moineddin; E J Crighton; M Mamdani
Journal:  Epidemiol Infect       Date:  2006-04-20       Impact factor: 2.451

3.  Mortality in children from influenza and respiratory syncytial virus.

Authors:  Douglas M Fleming; Rachel S Pannell; Kenneth W Cross
Journal:  J Epidemiol Community Health       Date:  2005-07       Impact factor: 3.710

Review 4.  Modelling hospital admissions for lower respiratory tract infections in the elderly in England.

Authors:  B Müller-Pebody; N S Crowcroft; M C Zambon; W J Edmunds
Journal:  Epidemiol Infect       Date:  2006-05-26       Impact factor: 2.451

5.  Monitoring mortality as an indicator of influenza in Catalonia, Spain.

Authors:  A Domínguez; P Muñoz; A Martínez; A Orcau
Journal:  J Epidemiol Community Health       Date:  1996-06       Impact factor: 3.710

Review 6.  Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma?

Authors:  J M Watson; J F Cordier; K G Nicholson
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

7.  Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein.

Authors:  Kalina T Zlateva; Philippe Lemey; Elien Moës; Anne-Mieke Vandamme; Marc Van Ranst
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

Review 8.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

Review 10.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.